<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03611439</url>
  </required_header>
  <id_info>
    <org_study_id>Genescient</org_study_id>
    <nct_id>NCT03611439</nct_id>
  </id_info>
  <brief_title>Effects of an 8 Component Botanical Supplement on Mild and Moderate Alzheimer's Patients</brief_title>
  <official_title>Effects of an 8 Component Botanical Supplement on Mild and Moderate Alzheimer's Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genescient Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genescient Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This placebo-controlled, double blind study evaluates the treatment effects of adding a
      multi-pathway botanical dietary supplement (ReBuilder) to the standard treatment regimens of
      subjects diagnosed with mild or moderate stage Alzheimer's Disease. The objective of the
      study is to determine if mild and moderate AD patients exhibit improved or stabilized
      cognitive function when this supplement is added to maximum tolerated doses of their standard
      treatments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, there is no treatment that can stop the progression of Alzheimer's Disease. The
      investigators in this study have used transgenic Drosophila melanogaster models and machine
      learning to develop an eight component botanical mixture (Geneaire™* ReBuilder™) that targets
      multiple genetic pathways involved in brain aging and dementia that are homologous between
      Drosophila and humans.

      While beta-amyloid plaques and phosphorylated-tau tangles are diagnostic for AD, the cause(s)
      of their soluble precursors that kill neurons has not been determined. The majority of AD
      patients are diagnosed after 60 years of age. Many studies point to aging related processes
      like inflammation, neural vascular damage, neural stress, altered cell metabolism,
      inefficient cellular autophagy, microglial dysfunction, mitochondrial dysfunction, and poor
      diet as potential causal factors in the decline of brain function over the decades that
      precede an actual AD diagnosis. AD is a multifaceted pathology involving many biochemical
      pathways and thus a multifaceted therapeutic approach may prove beneficial.

      The goal of this study was to test ReBuilder on human cognitive function. During the 12-month
      pilot study, the subjects were evaluated quarterly on the Mini Mental State Exam (MMSE),
      Alzheimer's Disease Cooperative Study's Activities of Daily Living (ADCS-ADL), and the
      Clinical Dementia Rating Sum of Boxes (CDR-SB).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2013</start_date>
  <completion_date type="Actual">December 25, 2015</completion_date>
  <primary_completion_date type="Actual">December 25, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, placebo-controlled, double blind study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>randomized, double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline Mini Mental State Exam (MMSE) Scores</measure>
    <time_frame>Change from baseline MMSE at 12 months</time_frame>
    <description>dementia questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Scores</measure>
    <time_frame>Change from baseline ADCS-ADL at 12 months</time_frame>
    <description>daily living activity questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline Clinical Dementia Rating Sum of Boxes (CDR-SB) Scores</measure>
    <time_frame>Change from baseline CDR-SB at 12 months</time_frame>
    <description>dementia assessment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Alzheimer Dementia</condition>
  <arm_group>
    <arm_group_label>ReBuilder Actives</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects take one 650 mg capsule by mouth twice a day for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ReBuilder Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects take one placebo capsule by mouth twice a day for 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ReBuilder</intervention_name>
    <description>8-component botanical dietary supplement</description>
    <arm_group_label>ReBuilder Actives</arm_group_label>
    <other_name>MX100A</other_name>
    <other_name>Memex+</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive Placebo Capsule</description>
    <arm_group_label>ReBuilder Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed mild or moderate Alzheimer's Disease

        Exclusion Criteria:

          -  History of heart disease

          -  History of heart attack

          -  History of cancer

          -  History of stroke or transient ischemic attack
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 17, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2018</study_first_posted>
  <last_update_submitted>July 26, 2018</last_update_submitted>
  <last_update_submitted_qc>July 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

